<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20230722062627&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20230722062627&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Sat, 22 Jul 2023 10:26:28 +0000</lastbuilddate>
<pubDate>Fri, 21 Jul 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Cardiovascular and dementia prevention: role of scores, diet, and rehabilitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37477627/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Jul 21;44(28):2501-2505. doi: 10.1093/eurheartj/ehad449.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37477627/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37477627</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad449>10.1093/eurheartj/ehad449</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37477627</guid>
<pubDate>Fri, 21 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-07-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiovascular and dementia prevention: role of scores, diet, and rehabilitation</dc:title>
<dc:identifier>pmid:37477627</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad449</dc:identifier>
</item>
<item>
<title>Global perspectives on heart disease rehabilitation and secondary prevention: a scientific statement from the Association of Cardiovascular Nursing and Allied Professions, European Association of Preventive Cardiology, and International Council of Cardiovascular Prevention and Rehabilitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37477626/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>Cardiovascular disease is a leading cause of death, morbidity, disability, and reduced health-related quality of life, as well as economic burden worldwide, with some 80% of disease burden occurring in the low- and middle-income country (LMIC) settings. With increasing numbers of people living longer with symptomatic disease, the effectiveness and accessibility of secondary preventative and rehabilitative health services have never been more important. Whilst LMICs experience the highest...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Jul 21;44(28):2515-2525. doi: 10.1093/eurheartj/ehad225.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular disease is a leading cause of death, morbidity, disability, and reduced health-related quality of life, as well as economic burden worldwide, with some 80% of disease burden occurring in the low- and middle-income country (LMIC) settings. With increasing numbers of people living longer with symptomatic disease, the effectiveness and accessibility of secondary preventative and rehabilitative health services have never been more important. Whilst LMICs experience the highest prevalence and mortality rates, the global approach to secondary prevention and cardiac rehabilitation, which mitigates this burden, has traditionally been driven from clinical guidelines emanating from high-income settings. This state-of-the art review provides a contemporary global perspective on cardiac rehabilitation and secondary prevention, contrasting the challenges of and opportunities for high vs. lower income settings. Actionable solutions to overcome system, clinician, programme, and patient level barriers to cardiac rehabilitation access in LMICs are provided.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37477626/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37477626</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad225>10.1093/eurheartj/ehad225</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37477626</guid>
<pubDate>Fri, 21 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Rod S Taylor</dc:creator>
<dc:creator>Suzanne Fredericks</dc:creator>
<dc:creator>Ian Jones</dc:creator>
<dc:creator>Lis Neubeck</dc:creator>
<dc:creator>Julie Sanders</dc:creator>
<dc:creator>Noemi De Stoutz</dc:creator>
<dc:creator>David R Thompson</dc:creator>
<dc:creator>Deepti N Wadhwa</dc:creator>
<dc:creator>Sherry L Grace</dc:creator>
<dc:date>2023-07-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Global perspectives on heart disease rehabilitation and secondary prevention: a scientific statement from the Association of Cardiovascular Nursing and Allied Professions, European Association of Preventive Cardiology, and International Council of Cardiovascular Prevention and Rehabilitation</dc:title>
<dc:identifier>pmid:37477626</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad225</dc:identifier>
</item>
<item>
<title>In This Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37477579/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Jul 21;133(3):197. doi: 10.1161/RES.0000000000000624. Epub 2023 Jul 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37477579/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37477579</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000624>10.1161/RES.0000000000000624</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37477579</guid>
<pubDate>Fri, 21 Jul 2023 06:00:00 -0400</pubDate>
<dc:date>2023-07-21</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>In This Issue</dc:title>
<dc:identifier>pmid:37477579</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000624</dc:identifier>
</item>
<item>
<title>Comparison of bleeding risk between standard ticagrelor and prasugrel therapies without de-escalation strategy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37477371/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Jul 21:ehad432. doi: 10.1093/eurheartj/ehad432. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37477371/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37477371</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad432>10.1093/eurheartj/ehad432</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37477371</guid>
<pubDate>Fri, 21 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Selçuk Şen</dc:creator>
<dc:date>2023-07-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Comparison of bleeding risk between standard ticagrelor and prasugrel therapies without de-escalation strategy</dc:title>
<dc:identifier>pmid:37477371</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad432</dc:identifier>
</item>
<item>
<title>Accelerated -Rule-Out of acute Myocardial Infarction using prehospital copeptin and in-hospital troponin: The AROMI study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37477353/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION: Accelerated dual marker rule-out of AMI, using a combination of prehospital copeptin and first in-hospital high-sensitivity troponin T, reduces length of hospital stay without increasing the rate of 30-day major adverse cardiac events as compared to using a 0 h/3 h rule-out strategy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Jul 21:ehad447. doi: 10.1093/eurheartj/ehad447. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">AIMS: The present acute myocardial infarction (AMI) rule-out strategies are challenged by the late temporal release of cardiac troponin. Copeptin is a non-specific biomarker of endogenous stress and rises early in AMI, covering the early period where troponin is still normal. An accelerated dual-marker rule-out strategy combining prehospital copeptin and in-hospital high-sensitivity troponin T could reduce length of hospital stay and thus the burden on the health care systems worldwide. The AROMI trial aimed to evaluate if the accelerated dual-marker rule-out strategy could safely reduce length of stay in patients discharged after early rule-out of AMI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: Patients with suspected AMI transported to hospital by ambulance were randomized 1:1 to either accelerated rule-out using copeptin measured in a prehospital blood sample and high-sensitivity troponin T measured at arrival to hospital or to standard rule-out using a 0 h/3 h rule-out strategy. The AROMI study included 4351 patients with suspected AMI. The accelerated dual-marker rule-out strategy reduced mean length of stay by 0.9 h (95% confidence interval 0.7-1.1 h) in patients discharged after rule-out of AMI and was non-inferior regarding 30-day major adverse cardiac events when compared to standard rule-out (absolute risk difference -0.4%, 95% confidence interval -2.5 to 1.7; P-value for non-inferiority = 0.013).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: Accelerated dual marker rule-out of AMI, using a combination of prehospital copeptin and first in-hospital high-sensitivity troponin T, reduces length of hospital stay without increasing the rate of 30-day major adverse cardiac events as compared to using a 0 h/3 h rule-out strategy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37477353/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37477353</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad447>10.1093/eurheartj/ehad447</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37477353</guid>
<pubDate>Fri, 21 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Claus Kjær Pedersen</dc:creator>
<dc:creator>Carsten Stengaard</dc:creator>
<dc:creator>Morten Thingemann Bøtker</dc:creator>
<dc:creator>Hanne Maare Søndergaard</dc:creator>
<dc:creator>Karen Kaae Dodt</dc:creator>
<dc:creator>Christian Juhl Terkelsen</dc:creator>
<dc:date>2023-07-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Accelerated -Rule-Out of acute Myocardial Infarction using prehospital copeptin and in-hospital troponin: The AROMI study</dc:title>
<dc:identifier>pmid:37477353</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad447</dc:identifier>
</item>
<item>
<title>Somatic mutations in vascular wall function and age-associated disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37477347/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Jul 21:ehad454. doi: 10.1093/eurheartj/ehad454. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37477347/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37477347</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad454>10.1093/eurheartj/ehad454</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37477347</guid>
<pubDate>Fri, 21 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Gwladys Revêchon</dc:creator>
<dc:creator>Lara Garcia Merino</dc:creator>
<dc:creator>Piotr Machtel</dc:creator>
<dc:creator>Maria Eriksson</dc:creator>
<dc:date>2023-07-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Somatic mutations in vascular wall function and age-associated disease</dc:title>
<dc:identifier>pmid:37477347</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad454</dc:identifier>
</item>
<item>
<title>New evidence supporting haemodynamics-guided remote management of congestion in heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37477224/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Jul 21:ehad435. doi: 10.1093/eurheartj/ehad435. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37477224/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37477224</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad435>10.1093/eurheartj/ehad435</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37477224</guid>
<pubDate>Fri, 21 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2023-07-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>New evidence supporting haemodynamics-guided remote management of congestion in heart failure</dc:title>
<dc:identifier>pmid:37477224</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad435</dc:identifier>
</item>
<item>
<title>Should the risk of atrial fibrillation deter PFO closure for cryptogenic ischaemic stroke?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37477208/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Jul 21:ehad425. doi: 10.1093/eurheartj/ehad425. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37477208/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37477208</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad425>10.1093/eurheartj/ehad425</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37477208</guid>
<pubDate>Fri, 21 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>A John Camm</dc:creator>
<dc:date>2023-07-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Should the risk of atrial fibrillation deter PFO closure for cryptogenic ischaemic stroke?</dc:title>
<dc:identifier>pmid:37477208</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad425</dc:identifier>
</item>
<item>
<title>Comparison of standard ticagrelor and prasugrel therapies based on previous trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37477206/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Jul 21:ehad433. doi: 10.1093/eurheartj/ehad433. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37477206/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37477206</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad433>10.1093/eurheartj/ehad433</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37477206</guid>
<pubDate>Fri, 21 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Jeehoon Kang</dc:creator>
<dc:creator>Kyung Woo Park</dc:creator>
<dc:creator>Hyo-Soo Kim</dc:creator>
<dc:date>2023-07-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Comparison of standard ticagrelor and prasugrel therapies based on previous trials</dc:title>
<dc:identifier>pmid:37477206</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad433</dc:identifier>
</item>
<item>
<title>Left main PCI: beware the circumflex!</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37477204/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Jul 21:ehad434. doi: 10.1093/eurheartj/ehad434. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37477204/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37477204</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad434>10.1093/eurheartj/ehad434</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37477204</guid>
<pubDate>Fri, 21 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Nils P Johnson</dc:creator>
<dc:creator>Jung-Min Ahn</dc:creator>
<dc:date>2023-07-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Left main PCI: beware the circumflex!</dc:title>
<dc:identifier>pmid:37477204</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad434</dc:identifier>
</item>
<item>
<title>EGFR/IGF1R Signaling Modulates Relaxation in Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37477020/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: We showed the feasibility of screening for functional modulators of cardiomyocyte relaxation and contraction, parameters that we observed to be modulated by kinases involved in EGFR/IGF1R, Akt, cell cycle signaling, and FoxO (forkhead box class O) signaling, respectively. Integrating the screening data with phosphoproteomics analysis in HCM patient tissue indicated that inhibition of EGFR/IGF1R signaling is a promising target for treating impaired relaxation in HCM.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Jul 21. doi: 10.1161/CIRCRESAHA.122.322133. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Diastolic dysfunction is central to diseases such as heart failure with preserved ejection fraction and hypertrophic cardiomyopathy (HCM). However, therapies that improve cardiac relaxation are scarce, partly due to a limited understanding of modulators of cardiomyocyte relaxation. We hypothesized that cardiac relaxation is regulated by multiple unidentified proteins and that dysregulation of kinases contributes to impaired relaxation in patients with HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We optimized and increased the throughput of unloaded shortening measurements and screened a kinase inhibitor library in isolated adult cardiomyocytes from wild-type mice. One hundred fifty-seven kinase inhibitors were screened. To assess which kinases are dysregulated in patients with HCM and could contribute to impaired relaxation, we performed a tyrosine and global phosphoproteomics screen and integrative inferred kinase activity analysis using HCM patient myocardium. Identified hits from these 2 data sets were validated in cardiomyocytes from a homozygous <i>MYBPC3</i><sub>c.2373insG</sub> HCM mouse model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Screening of 157 kinase inhibitors in wild-type (n=33) cardiomyocytes (n=24 563) resulted in the identification of 17 positive inotropes and 21 positive lusitropes, almost all of them novel. The positive lusitropes formed 3 clusters: cell cycle, EGFR (epidermal growth factor receptor)/IGF1R (insulin-like growth factor 1 receptor), and a small Akt (α-serine/threonine protein kinase) signaling cluster. By performing phosphoproteomic profiling of HCM patient myocardium (n=24 HCM and n=8 donors), we demonstrated increased activation of 6 of 8 proteins from the EGFR/IGFR1 cluster in HCM. We validated compounds from this cluster in mouse HCM (n=12) cardiomyocytes (n=2023). Three compounds from this cluster were able to improve relaxation in HCM cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We showed the feasibility of screening for functional modulators of cardiomyocyte relaxation and contraction, parameters that we observed to be modulated by kinases involved in EGFR/IGF1R, Akt, cell cycle signaling, and FoxO (forkhead box class O) signaling, respectively. Integrating the screening data with phosphoproteomics analysis in HCM patient tissue indicated that inhibition of EGFR/IGF1R signaling is a promising target for treating impaired relaxation in HCM.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37477020/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37477020</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.122.322133>10.1161/CIRCRESAHA.122.322133</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37477020</guid>
<pubDate>Fri, 21 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Sila Algül</dc:creator>
<dc:creator>Maike Schuldt</dc:creator>
<dc:creator>Emmy Manders</dc:creator>
<dc:creator>Valentijn Jansen</dc:creator>
<dc:creator>Saskia Schlossarek</dc:creator>
<dc:creator>Richard de Goeij-de Haas</dc:creator>
<dc:creator>Alex A Henneman</dc:creator>
<dc:creator>Sander R Piersma</dc:creator>
<dc:creator>Connie R Jimenez</dc:creator>
<dc:creator>Michelle Michels</dc:creator>
<dc:creator>Lucie Carrier</dc:creator>
<dc:creator>Michiel Helmes</dc:creator>
<dc:creator>Jolanda van der Velden</dc:creator>
<dc:creator>Diederik W D Kuster</dc:creator>
<dc:date>2023-07-21</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>EGFR/IGF1R Signaling Modulates Relaxation in Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:37477020</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.122.322133</dc:identifier>
</item>
<item>
<title>A novel prediction model for pulmonary embolism: from dichotomizing algorithms to personalized likelihood</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37475706/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Jul 21:ehad392. doi: 10.1093/eurheartj/ehad392. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37475706/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37475706</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad392>10.1093/eurheartj/ehad392</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37475706</guid>
<pubDate>Fri, 21 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Thomas A Zelniker</dc:creator>
<dc:creator>Irene M Lang</dc:creator>
<dc:date>2023-07-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A novel prediction model for pulmonary embolism: from dichotomizing algorithms to personalized likelihood</dc:title>
<dc:identifier>pmid:37475706</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad392</dc:identifier>
</item>
<item>
<title>De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37474795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y purinoceptor 12 (P2Y(12)) inhibitor (prasugrel or ticagrelor) for 12 months. Although this approach reduces ischaemic risk, patients are exposed to a substantial risk of bleeding. Strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y(12) inhibitor at conventional doses to either...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Jul 20. doi: 10.1038/s41569-023-00901-2. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y purinoceptor 12 (P2Y<sub>12</sub>) inhibitor (prasugrel or ticagrelor) for 12 months. Although this approach reduces ischaemic risk, patients are exposed to a substantial risk of bleeding. Strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y<sub>12</sub> inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. Either strategy requires assessment of the ischaemic and bleeding risks of each individual. De-escalation of DAPT intensity can reduce bleeding without increasing ischaemic events and can be guided by platelet function testing or genotyping. Abbreviation of DAPT duration after 1-6 months, followed by monotherapy with aspirin or a P2Y<sub>12</sub> inhibitor, reduces bleeding without an increase in ischaemic events in patients at high bleeding risk, particularly those without high ischaemic risk. However, these two strategies have not yet been compared in a head-to-head clinical trial. In this Consensus Statement, we summarize the evidence base for these treatment approaches, provide guidance on the assessment of ischaemic and bleeding risks, and provide consensus statements from an international panel of experts to help clinicians to optimize these DAPT approaches for individual patients to improve outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37474795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37474795</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00901-2>10.1038/s41569-023-00901-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37474795</guid>
<pubDate>Thu, 20 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Diana A Gorog</dc:creator>
<dc:creator>Jose Luis Ferreiro</dc:creator>
<dc:creator>Ingo Ahrens</dc:creator>
<dc:creator>Junya Ako</dc:creator>
<dc:creator>Tobias Geisler</dc:creator>
<dc:creator>Sigrun Halvorsen</dc:creator>
<dc:creator>Kurt Huber</dc:creator>
<dc:creator>Young-Hoon Jeong</dc:creator>
<dc:creator>Eliano P Navarese</dc:creator>
<dc:creator>Andrea Rubboli</dc:creator>
<dc:creator>Dirk Sibbing</dc:creator>
<dc:creator>Jolanta M Siller-Matula</dc:creator>
<dc:creator>Robert F Storey</dc:creator>
<dc:creator>Jack W C Tan</dc:creator>
<dc:creator>Jurrien M Ten Berg</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Christophe Vandenbriele</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:date>2023-07-20</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis</dc:title>
<dc:identifier>pmid:37474795</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00901-2</dc:identifier>
</item>
<item>
<title>2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37471501/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>AIM The "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease" provides an update to and consolidates new evidence since the "2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease" and the corresponding "2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease." Methods A comprehensive...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Jul 20. doi: 10.1161/CIR.0000000000001168. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">AIM The "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease" provides an update to and consolidates new evidence since the "2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease" and the corresponding "2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease." Methods A comprehensive literature search was conducted from September 2021 to May 2022. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants were identified that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Structure This guideline provides an evidenced-based and patient-centered approach to management of patients with chronic coronary disease, considering social determinants of health and incorporating the principles of shared decision-making and team-based care. Relevant topics include general approaches to treatment decisions, guideline-directed management and therapy to reduce symptoms and future cardiovascular events, decision-making pertaining to revascularization in patients with chronic coronary disease, recommendations for management in special populations, patient follow-up and monitoring, evidence gaps, and areas in need of future research. Where applicable, and based on availability of cost-effectiveness data, cost-value recommendations are also provided for clinicians. Many recommendations from previously published guidelines have been updated with new evidence, and new recommendations have been created when supported by published data.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37471501/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37471501</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001168>10.1161/CIR.0000000000001168</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37471501</guid>
<pubDate>Thu, 20 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Salim S Virani</dc:creator>
<dc:creator>L Kristin Newby</dc:creator>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>Vera Bittner</dc:creator>
<dc:creator>LaPrincess C Brewer</dc:creator>
<dc:creator>Susan Halli Demeter</dc:creator>
<dc:creator>Dave L Dixon</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Beverly Hess</dc:creator>
<dc:creator>Heather M Johnson</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:creator>Dhaval Kolte</dc:creator>
<dc:creator>Dharam J Kumbhani</dc:creator>
<dc:creator>Jim LoFaso</dc:creator>
<dc:creator>Dhruv Mahtta</dc:creator>
<dc:creator>Daniel B Mark</dc:creator>
<dc:creator>Margo Minissian</dc:creator>
<dc:creator>Ann Marie Navar</dc:creator>
<dc:creator>Amit R Patel</dc:creator>
<dc:creator>Mariann R Piano</dc:creator>
<dc:creator>Fatima Rodriguez</dc:creator>
<dc:creator>Amy W Talbot</dc:creator>
<dc:creator>Viviany R Taqueti</dc:creator>
<dc:creator>Randal J Thomas</dc:creator>
<dc:creator>Sean van Diepen</dc:creator>
<dc:creator>Barbara Wiggins</dc:creator>
<dc:creator>Marlene S Williams</dc:creator>
<dc:date>2023-07-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:37471501</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001168</dc:identifier>
</item>
<item>
<title>Correction to: Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37471489/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Jul 21;133(3):e49. doi: 10.1161/RES.0000000000000623. Epub 2023 Jul 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37471489/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37471489</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000623>10.1161/RES.0000000000000623</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37471489</guid>
<pubDate>Thu, 20 Jul 2023 06:00:00 -0400</pubDate>
<dc:date>2023-07-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Correction to: Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations</dc:title>
<dc:identifier>pmid:37471489</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000623</dc:identifier>
</item>
<item>
<title>Correction to: SIRT6 Mitigates Heart Failure With Preserved Ejection Fraction in Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37471488/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Jul 21;133(3):e48. doi: 10.1161/RES.0000000000000622. Epub 2023 Jul 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37471488/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37471488</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000622>10.1161/RES.0000000000000622</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37471488</guid>
<pubDate>Thu, 20 Jul 2023 06:00:00 -0400</pubDate>
<dc:date>2023-07-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Correction to: SIRT6 Mitigates Heart Failure With Preserved Ejection Fraction in Diabetes</dc:title>
<dc:identifier>pmid:37471488</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000622</dc:identifier>
</item>
<item>
<title>p53 at the Intersection of Cardiac Fibroblast Proliferation and Activation: Answers and Questions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37471487/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Jul 21;133(3):288-290. doi: 10.1161/CIRCRESAHA.123.323209. Epub 2023 Jul 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37471487/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37471487</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323209>10.1161/CIRCRESAHA.123.323209</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37471487</guid>
<pubDate>Thu, 20 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Alessandra Ghigo</dc:creator>
<dc:creator>Pietro Ameri</dc:creator>
<dc:date>2023-07-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>p53 at the Intersection of Cardiac Fibroblast Proliferation and Activation: Answers and Questions</dc:title>
<dc:identifier>pmid:37471487</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323209</dc:identifier>
</item>
<item>
<title>Cardiac Fibrosis Mitigated by an Endogenous Negative Regulator of HDAC</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37471486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Jul 21;133(3):252-254. doi: 10.1161/CIRCRESAHA.123.323211. Epub 2023 Jul 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37471486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37471486</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323211>10.1161/CIRCRESAHA.123.323211</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37471486</guid>
<pubDate>Thu, 20 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Michael P Lazaropoulos</dc:creator>
<dc:creator>John W Elrod</dc:creator>
<dc:date>2023-07-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cardiac Fibrosis Mitigated by an Endogenous Negative Regulator of HDAC</dc:title>
<dc:identifier>pmid:37471486</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323211</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37471484/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Jul 21;133(3):198-199. doi: 10.1161/RES.0000000000000625. Epub 2023 Jul 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37471484/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37471484</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000625>10.1161/RES.0000000000000625</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37471484</guid>
<pubDate>Thu, 20 Jul 2023 06:00:00 -0400</pubDate>
<dc:date>2023-07-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:37471484</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000625</dc:identifier>
</item>
<item>
<title>Chronic Coronary Disease Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37471475/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Jul 20. doi: 10.1161/CIRCULATIONAHA.123.064623. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37471475/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37471475</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064623>10.1161/CIRCULATIONAHA.123.064623</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37471475</guid>
<pubDate>Thu, 20 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Sunil V Rao</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>Judith S Hochman</dc:creator>
<dc:date>2023-07-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Chronic Coronary Disease Guidelines</dc:title>
<dc:identifier>pmid:37471475</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064623</dc:identifier>
</item>
<item>
<title>Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37470202/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230722062627&amp;v=2.17.9.post6+86293ac
      <description>The current treatment algorithm for chronic thromboembolic pulmonary hypertension (CTEPH) as depicted in the 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines on the diagnosis and treatment of pulmonary hypertension (PH) includes a multimodal approach of combinations of pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA) and medical therapies to target major vessel pulmonary vascular lesions, and microvasculopathy. Today, BPA of >;1700...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Jul 20:ehad413. doi: 10.1093/eurheartj/ehad413. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The current treatment algorithm for chronic thromboembolic pulmonary hypertension (CTEPH) as depicted in the 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines on the diagnosis and treatment of pulmonary hypertension (PH) includes a multimodal approach of combinations of pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA) and medical therapies to target major vessel pulmonary vascular lesions, and microvasculopathy. Today, BPA of >;1700 patients has been reported in the literature from centers in Asia, the US, and also Europe; many more patients have been treated outside literature reports. As BPA becomes part of routine care of patients with CTEPH, benchmarks for safe and effective care delivery become increasingly important. In light of this development, the ESC Working Group on Pulmonary Circulation and Right Ventricular Function has decided to publish a document that helps standardize BPA to meet the need of uniformity in patient selection, procedural planning, technical approach, materials and devices, treatment goals, complications including their management, and patient follow-up, thus complementing the guidelines. Delphi methodology was utilized for statements that were not evidence based. First, an anatomical nomenclature and a description of vascular lesions are provided. Second, treatment goals and definitions of complete BPA are outlined. Third, definitions of complications are presented which may be the basis for a standardized reporting in studies involving BPA. The document is intended to serve as a companion to the official ESC/ERS guidelines.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37470202/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230722062627&v=2.17.9.post6+86293ac">37470202</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad413>10.1093/eurheartj/ehad413</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37470202</guid>
<pubDate>Thu, 20 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Irene M Lang</dc:creator>
<dc:creator>Arne K Andreassen</dc:creator>
<dc:creator>Asger Andersen</dc:creator>
<dc:creator>Helene Bouvaist</dc:creator>
<dc:creator>Gerry Coghlan</dc:creator>
<dc:creator>Pilar Escribano-Subias</dc:creator>
<dc:creator>Pavel Jansa</dc:creator>
<dc:creator>Grzegorz Kopec</dc:creator>
<dc:creator>Marcin Kurzyna</dc:creator>
<dc:creator>Hiromi Matsubara</dc:creator>
<dc:creator>Bernhard Christian Meyer</dc:creator>
<dc:creator>Massimiliano Palazzini</dc:creator>
<dc:creator>Marco C Post</dc:creator>
<dc:creator>Piotr Pruszczyk</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:creator>Marek Roik</dc:creator>
<dc:creator>Stephan Rosenkranz</dc:creator>
<dc:creator>Christoph B Wiedenroth</dc:creator>
<dc:creator>Carlo Redlin-Werle</dc:creator>
<dc:creator>Philippe Brenot</dc:creator>
<dc:date>2023-07-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function</dc:title>
<dc:identifier>pmid:37470202</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad413</dc:identifier>
</item>





























</channel>
</rss>